Alterations of the Treatment-Naive Gut Microbiome in Newly Diagnosed Hepatitis C Virus Infection.
Salma SultanMohammed El-MowafyAbdelaziz ElgamlMohamed El-MeseryAhmed El ShabrawiMohamed ElegezyRiadh HammamiWalid MottaweaPublished in: ACS infectious diseases (2020)
Gut microbiota dysbiosis has been linked to many heath disorders including hepatitis C virus (HCV) infection. However, profiles of the gut microbiota alterations in HCV are inconsistent in the literature and are affected by the treatment regimens. Using samples collected prior to treatment from newly diagnosed patients, we characterized the gut microbiota structure in HCV patients as compared to healthy controls. Treatment-naive HCV microbiota showed increased diversity, an increased abundance of Prevotella, Succinivibrio, Catenibacterium, Megasphaera, and Ruminococcaceae, and a lower abundance of Bacteroides, Dialister, Bilophila, Streptococcus, parabacteroides, Enterobacteriaceae, Erysipelotrichaceae, Rikenellaceae, and Alistipes. Predicted community metagenomic functions showed a depletion of carbohydrate and lipid metabolism in HCV microbiota along with perturbations of amino acid metabolism. Receiver-operating characteristic analysis identified five disease-specific operational taxonomic units (OTUs) as potential biomarkers of HCV infections. Collectively, our findings reveal the alteration of gut microbiota in treatment naive HCV patients and suggest that gut microbiota may hold diagnostic promise in HCV infection.
Keyphrases
- hepatitis c virus
- newly diagnosed
- end stage renal disease
- human immunodeficiency virus
- ejection fraction
- chronic kidney disease
- systematic review
- peritoneal dialysis
- prognostic factors
- hiv infected
- gene expression
- dna methylation
- amino acid
- antibiotic resistance genes
- genome wide
- combination therapy
- single cell
- candida albicans
- smoking cessation